drugset / Trial / NCT06743945
POLA-R-CHP in the First-line Treatment of Transformed DLBCL
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.
Timeline
- Start
- 2025-02-17
- Primary completion
- 2027-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polatuzumab Vedotin | Other / unclassified | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |